Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personalized DNA Immunotherapy

On November 2, 2026 Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen targeted personalized DNA immunotherapy for cancer (PIC), reported upcoming presentations sharing clinical data in brain cancer patients. The first presentation showcases sustained immunosurveillance in two high grade glioma patients receiving PIC following surgery and radiation, which led to exceptionally durable progression-free survival (>5 years from surgery). A second presentation discusses characterization of the tumor microenvironment in the brain following PIC treatment. These data will be presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day taking place in Philadelphia, Pennsylvania from November 12-15.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentations are as follows:

Poster Title: Long-term neoantigen-targeted personalized immunotherapy for cancer (PIC) drives sustained immunosurveillance in brain cancer patients and offers a path to dynamic therapy

Presenting Author: Tanner Johanns, Washington University School of Medicine, St. Louis, MO
Abstract Number: CTIM-23

Session Date and Time: Friday, November 13, 2026, 7:30-9:30 pm

Location: Exhibit Halls D and E, Philadelphia Convention Center

Poster Title: Characterizing the tumor immune microenvironment following neoantigen-targeted personalized immunotherapy for cancer (PIC) in glioblastoma using spatial profiling

Presenting Author: Elizabeth A. R. Garfinkle, The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, OH

Abstract Number: TMIC-57

Session Date and Time: Friday, November 13, 2026, 7:30-9:30 pm

Location: Exhibit Halls D and E, Philadelphia Convention Center

(Press release, Geneos Therapeutics, NOV 2, 2026, View Source [SID1234674050])